Offspring of Mothers with Hyperglycemia in Pregnancy: Short-Term Consequences for Newborns and Infants

2019 ◽  
pp. 194-200
Author(s):  
Jean-Baptiste Armengaud ◽  
Umberto Simeoni
Keyword(s):  
1989 ◽  
Vol 28 (4) ◽  
pp. 331-335
Author(s):  
A.A. Edebiri ◽  
D.S. Mack ◽  
D.J. McDonald ◽  
J. Philips

2018 ◽  
Vol 145 ◽  
pp. 155-166 ◽  
Author(s):  
Jean-Baptiste Armengaud ◽  
Ronald C.W. Ma ◽  
Benazir Siddeek ◽  
Gerard H.A. Visser ◽  
Umberto Simeoni

1992 ◽  
Vol 262 (6) ◽  
pp. R966-R974 ◽  
Author(s):  
S. Schenker ◽  
R. F. Johnson ◽  
J. D. Mahuren ◽  
G. I. Henderson ◽  
S. P. Coburn

The aims of this study were to define normal human placental transport of pyridoxal, an important form of vitamin B6 in pregnancy, and to determine the effect of short-term alcohol on this process. Our studies used the isolated single cotyledon from the term placenta. Pyridoxal crossed the human placenta readily in both directions, but the transfer was a little less than half that of antipyrine and was significantly greater in the direction of the fetus. Pyridoxine appeared to have a similar clearance from the maternal compartment as pyridoxal, but transport of intact pyridoxal 5'-phosphate was much smaller. There was no saturable transfer of pyridoxal, and it was not transferred from the maternal to fetal compartments against a concentration gradient. Placental concentration of pyridoxal exceeded both maternal and fetal perfusate pyridoxal concentrations, but this concentration was equal for both perfusion directions. These composite data are most suggestive of passive transport of pyridoxal across the placenta, binding of the vitamin in the placenta as an explanation for its concentration there, and greater phosphorylation of pyridoxal in the placenta when the compound is transferred in the fetal direction, possibly displacing pyridoxal from its binding sites and permitting its greater release into the fetal compartment. Alcohol, 400-250 mg/dl over 2.5 h, inhibited the transport of pyridoxal from the maternal to fetal compartments by approximately 42% (P = 0.03) and resulted in a lower transfer of pyridoxal 5'-phosphate into the fetal perfusate (P = 0.02).


Author(s):  
Claire L Meek

Despite recent advances in care, women with diabetes in pregnancy are still at increased risk of multiple pregnancy complications. Offspring exposed to hyperglycaemia in utero also experience long-term health sequelae affecting neurocognitive and cardiometabolic status. Many of these adverse consequences can be prevented or ameliorated with good medical care, specifically to optimise glycaemic control. The accurate assessment of glycaemia in pregnancy is therefore vital to safeguard the health of mother and child. However, there is no consensus about the best method of monitoring glycaemic control in pregnancy. Short-term changes in insulin dosage and lifestyle, with altered appetite, insulin sensitivity and red cell turnover create difficulties in interpretation of standard laboratory measures such as HbA1c. The ideal marker would provide short-term feedback on daily or weekly glycaemic control, with additional capability to predict pregnancies at high risk of suboptimal outcomes. Several novel biochemical markers are available which allow assessment of dynamic changes in glycaemia over weeks rather than months. Continuous glucose monitoring devices have advanced in accuracy and provide new opportunities for robust assessment of glycaemia in pregnancy. Recent work from the continuous glucose monitoring in pregnant women with type 1 diabetes trial (CONCEPTT) has provided information about the ability of different markers of glycaemia to predict pregnancy outcomes. The aim of this review is to summarise the care for women with pre-existing diabetes in pregnancy, and to highlight the important role of glycaemic monitoring in pregnancy.


Author(s):  
SVEN MONTAN ◽  
HANS LIEDHOLM ◽  
GORAN LINGMAN ◽  
KAREL MARSAL ◽  
NILS-OTTO SJOBERG ◽  
...  

1982 ◽  
Vol 1 (2) ◽  
pp. 57-61 ◽  
Author(s):  
S. Campbell ◽  
A. E. Reading ◽  
D. N. Cox ◽  
C. M. Sledmere ◽  
R. Mooney ◽  
...  

2002 ◽  
Vol 6 (6) ◽  
pp. 561-570 ◽  
Author(s):  
Amanda E. Tauscher ◽  
Alan B. Fleischer ◽  
Kathy C. Phelps ◽  
Steven R. Feldman

Background: Women comprise half of all psoriasis patients and because the majority of psoriasis cases present before age 40 the disease affects women who may become pregnant. Information regarding the heritability of psoriasis can be used in counseling patients who inquire about the potential risk to their children. Patients with psoriasis who become pregnant will likely notice an associated improvement of their symptoms if any change is noted at all. Objective: Because of potential fetal effects, the treatment of chronic psoriasis in pregnancy involves prudent consideration of whether the severity of the disease warrants treatment and selection of the safest treatments available. Conclusion: Topical corticosteroids and topical calcipotriene as well as topical anthralin and topical tacrolimus appear to be safe choices for control of localized psoriasis in pregnancy. UVB is the safest treatment for extensive psoriasis during pregnancy, particularly when topical application of other agents is not practical. Short-term use of cyclosporine during pregnancy is probably the safest option for management of severe psoriasis that has not responded to topical or UVB treatment.


2016 ◽  
Vol 214 (6) ◽  
pp. 723.e1-723.e11 ◽  
Author(s):  
Lisa R. Leffert ◽  
Caitlin R. Clancy ◽  
Brian T. Bateman ◽  
Margueritte Cox ◽  
Phillip J. Schulte ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document